|1.||WO||WO/2013/143508 - METHOD FOR SIMULTANEOUS DETECTION, RECOVERY, IDENTIFICATION AND COUNTING OF MICROORGANISMS AND DEVICES FOR THE IMPLEMENTATION OF SAID METHOD||03.10.2013||
||PCT/CU2013/000002||CENTRO NACIONAL DE BIOPREPARADOS (BIOCEN)||RODRÍGUEZ MARTÍNEZ, Claudio|
The present invention describes a method and devices for the simultaneous detection, recovery, identification and counting of a plurality of microorganisms consisting in providing mixtures of nutrients specially selected from those that curtail the lag phase of growth in bacteria and moulds and which, together with fluorescent enzymatic, chromogenic or bioluminescent markers and other nutrient components or growth inhibitors, are embedded in three-dimensional structures or natural or artificial clays or ceramics with cavities of different dimensions and forms and specific surface areas of between 2 × 103 and 6 × 108 m2/m3.
|2.||WO||WO/2013/127373 - RECOMBINANT ANTIBODIES HAVING DUAL SPECIFICITY FOR GANGLIOSIDES AND USE THEREOF||06.09.2013||
|PCT/CU2013/000001||CENTRO DE INMUNOLOGIA MOLECULAR||MORENO FRIAS, Ernesto|
The present invention relates to novel monoclonal antibodies and fragments of said antibodies, which have dual specificity and a high affinity for the gangliosides N-acetyl GM3 and N-glicolyl GM3, and which do not recognize other gangliosides. According to another aspect, the present invention relates to the use of said antibodies and the fragments thereof in tumor therapy, in which said tumors have a significant expression of any of the two antigens recognized by said antibodies, or a mixed expression of both antigens. The invention also relates to a use of said antibodies in the diagnosis of tumors that express at least one of the antigens.
|3.||WO||WO/2013/113296 - COMPOSITION FROM LOBSTER HEMOCYTE EXTRACT FOR DETECTION OF LIPOPOLYSACCHARIDES, PEPTIDOGLYCANS AND 1,3-BETA-D-GLUCANS||08.08.2013||
|PCT/CU2012/000009||CENTRO DE INVESTIGACION Y DESARROLLO DE LOS MEDICAMENTOS(CIDEM)||PERDOMO MORALES, Rolando|
The present invention relates to the field of pharmaceuticals, chemistry and biotechnology and, in particular, to a method for preparing a composition for detecting and measuring the concentration of endotoxins or lipopolysaccharides, peptidoglycans and (1,3)-β-D-glucans, using a lobster hemocyte extract as starting material, to the modifications of the composition for increasing the sensitivity thereof, and to the methods for measuring endotoxins, peptidoglycans and (1,3)-β-D-glucans using said composition.
|4.||WO||WO/2013/097834 - PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF TUMOURS THAT EXPRESS EGFR AND GANGLIOSIDE N-GLYCOLYL GM3 (NEUGCGM3)||04.07.2013||
|PCT/CU2012/000007||CENTRO DE INMUNOLOGIA MOLECULAR||GONZÁLEZ PALOMO, Adys|
The invention relates to pharmaceutical composition for the treatment of malignant tumours, in particular tumours that express EGFR and N-glycolyl GM3 ganglioside targets, in order to enhance the therapeutic effect produced individually by therapies against said targets. The pharmaceutical compositions of the invention comprise antibodies and/or vaccines against each of the targets. In addition, the invention relates to the methods used to apply the compositions of the invention.
|5.||WO||WO/2013/097835 - SPIROSTEROIDAL SYSTEMS HAVING NEUROACTIVE, ANTI-INFLAMMATORY EFFECTS||04.07.2013||
|PCT/CU2012/000008||CENTRO DE INVESTIGACION Y DESARROLLO DE LOS MEDICAMENTOS (CIDEM)||GARCIA PUPO, Laura|
The present invention relates to the fields of chemistry and pharmaceuticals and, in particular, to obtaining novel molecular entities — steroid derivatives — that affect the central nervous system. Diosgenin, which is a natural sapogenin, is used to obtain hexacyclic spirostanic steroid derivatives with the general formula I-IV, by reaction with compounds that can be oxidising, epoxidising, etc., as well as subsequent transformations of some of the latter. The molecular entities with the general formula I-IV contain the cyclopentanoperhydrophenanthrene core, in which the cycle A consists of spirostanic rings replaced with various electronegative atoms. Said molecular entities have anti-glutamatergic and anti-inflammatory action, and can be used for treating chronic and acute inflammatory, neurodegenerative, neuropsychiatric and neurological diseases.
|6.||WO||WO/2013/064129 - ADJUVANTS FOR POLYSACCHARIDE VACCINES AND RESULTING FORMULATIONS||10.05.2013||
|PCT/CU2012/000006||INSTITUTO FINLAY. CENTRO DE INVESTIGACIÓN- PRODUCCIÓN DE SUEROS Y VACUNAS.||PEREZ MARTÍN, Oliver Germán|
The invention relates to immunogenic compositions for mucosal and parenteral application, comprising (1) a single capsular saccharide or multiple unconjugated bacteria and (2) potent adjuvants. Plain oligosaccharides or polysaccharides are preferred, without excluding the addition of potent adjuvants to conjugated polysaccharides. Preferably, the adjuvants are Adjuvant Finlay Cocleato x (AFCox) or Adjuvant Finlay Proteoliposome x (AFPLx). Mucosal delivery is preferred, without excluding parenteral delivery or combinations of both. The invention also relates to immunogenic compositions (a) a capsular saccharide antigen from serogroup C or serogroup A of Neisseria meningitidis; (b) AFPL1 adjuvants absorbed in alumina by parenteral route or non-absorbed AFPL1 or AFCol by nasal route; and (c) the application of both parenteral and mucosal priming simultaneously along with any of the potent adjuvants formulated with the aforementioned antigens. The use of potent adjuvants formulated with unconjugated polysaccharides increases the systemic mucosal immune response, polarising the independent Timo response of the polysaccharides to a dependent Timo response with a Th1 cellular pattern that guarantees the function thereof in small children and induces immune memory without requiring covalent conjugation.
|7.||WO||WO/2013/044890 - AMINO ACID SEQUENCES FOR CONTROLLING PATHOGENS||04.04.2013||
|PCT/CU2012/000005||CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA||ACOSTA ALBA, Jannel|
The invention relates to isolated and purified antimicrobial peptides from tilapia (Oreochromis niloticus) gill extracts. Said peptides can be produced by chemical synthesis or in heterologous expression systems, such as bacteria and yeast, by conventional molecular biology techniques. Said peptides exhibit antimicrobial activity against various organisms including gram-positive bacteria, gram-negative bacteria, fungi and viruses. The invention also includes compositions for controlling pathogenic agents, comprising said antimicrobial peptides. The invention further relates to the use of said peptides as a molecular adjuvant in vaccine preparations.
|8.||WO||WO/2013/029570 - USE OF THE PACAP AS A MOLECULAR ADJUVANT FOR VACCINES||07.03.2013||
|PCT/CU2012/000004||CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA||LUGO GONZÁLEZ, Juana, María|
The invention relates to the use of the pituitary adenylate cyclase-activating polypeptide (PACAP) as a molecular adjuvant for vaccines. Along with other applications, said vaccines can be used for protection against infectious agents such as viruses, bacteria and ectoparasites that affect mammals, birds and aquatic organisms. The PACAP, combined with a specific antigen, exhibits the effectiveness thereof as an adjuvant as it increases the immunological response of the host against said antigen. This type of response can be observed when the vaccine compositions or combinations comprising PACAP are administered orally, by an injection, or by dipping tanks in the case of aquatic organisms.
|9.||WO||WO/2013/004203 - COMPOUNDS AND PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND ISCHEMIC BRAIN DISEASES||10.01.2013||
|PCT/CU2012/000003||CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA||PENTON ROL, Giselle|
The invention relates to peptides comprising phycocyanobilin (PCB), as well as to the use of said peptides and PCB in medicine owing to the neuroprotective and/or neurogenerative effects thereof that have been identified. In addition, the invention relates to pharmaceutical combinations of said peptides and PCB with proteins or other peptides which, owing to the synergistic effect thereof, are suitable for use in the treatment of diseases of the central nervous system involving neurodegenerative and ischemic damage.
|10.||WO||WO/2012/126441 - CYCLIC PEPTIDES WITH AN ANTI-NEOPLASIC AND ANTI-ANGIOGENIC ACTIVITY||27.09.2012||
|PCT/CU2012/000002||CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA||ABRAHANTES PÉREZ, María, del Carmen|
The invention relates to cyclic peptides having anti-tumoral and anti-angiogenic properties, and to the pharmaceutically acceptable salts thereof and the pharmaceutical compositions containing same. Said cyclic peptides are used in the preparation of medicaments for human and/or veterinary therapeutics and can also be used in diagnostics. Said compounds can be used to detect, monitor and/or control a variety of disorders relating to cellular proliferation, such as oncological diseases and unwanted angiogenesis. Furthermore, they can form part of controlled release systems and systems pertaining to the field of nanobiotechnology, due to the self-assembly capacity thereof and as part of other systems.